Targeting IDH1 and IDH2 mutations in acute myeloid leukemia
BK Ragon, CD DiNardo - Current hematologic malignancy reports, 2017 - Springer
Abstract Purpose of Review Over the past decade, the pathogenic role of mutations in
isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML …
isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML …
IDH1/IDH2 inhibition in acute myeloid leukemia
C Cerchione, A Romano, N Daver, C DiNardo… - Frontiers in …, 2021 - frontiersin.org
Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2
mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of …
mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of …
Targeting the IDH2 Pathway in Acute Myeloid Leukemia
ML Amaya, DA Pollyea - Clinical Cancer Research, 2018 - AACR
Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. A large
percentage of patients succumb to this disease in spite of aggressive treatments with …
percentage of patients succumb to this disease in spite of aggressive treatments with …
The role of IDH mutations in acute myeloid leukemia
G Montalban-Bravo, CD DiNardo - Future Oncology, 2018 - Taylor & Francis
Isocitrate dehydrogenases (IDHs) are enzymes involved in multiple metabolic and
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
GC Issa, CD DiNardo - Blood cancer journal, 2021 - nature.com
Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …
IDH inhibitors in AML—promise and pitfalls
H McMurry, L Fletcher, E Traer - Current hematologic malignancy reports, 2021 - Springer
Abstract Purpose of Review Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2)
are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases …
are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases …
IDH2 mutations in acute myeloid leukemia
R Babakhanlou, C DiNardo, G Borthakur - Leukemia & Lymphoma, 2023 - Taylor & Francis
Advances in the treatment of acute myeloid leukemia (AML) over the last 40 years have
been limited. With an improved understanding of the pathophysiology of the disease, the …
been limited. With an improved understanding of the pathophysiology of the disease, the …
Therapeutic targeting of isocitrate dehydrogenase mutant AML
P Boddu, G Borthakur - Expert Opinion on Investigational Drugs, 2017 - Taylor & Francis
The last decade has witnessed rapid advances in our understanding of molecular
leukemogenesis providing valuable insights from which to explore new therapeutic …
leukemogenesis providing valuable insights from which to explore new therapeutic …
SOHO state of the art update and next questions: IDH therapeutic targeting in AML
CD DiNardo, EM Stein - Clinical Lymphoma Myeloma and Leukemia, 2018 - Elsevier
Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of
patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid …
patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid …
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
F Thol, F Damm, K Wagner, G Göhring… - Blood, The Journal …, 2010 - ashpublications.org
Mutations in the nicotinamide adenine dinucleotide phosphate+–dependent isocitrate
dehydrogenase gene 2 (IDH2) have recently been found in patients with acute myeloid …
dehydrogenase gene 2 (IDH2) have recently been found in patients with acute myeloid …